B
Brent A. Neuschwander-Tetri
Researcher at Saint Louis University
Publications - 203
Citations - 29303
Brent A. Neuschwander-Tetri is an academic researcher from Saint Louis University. The author has contributed to research in topics: Nonalcoholic fatty liver disease & Steatohepatitis. The author has an hindex of 58, co-authored 183 publications receiving 23528 citations. Previous affiliations of Brent A. Neuschwander-Tetri include University of Pittsburgh & University of Bari.
Papers
More filters
Journal ArticleDOI
Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions
Elizabeth M. Brunt,Christine G. Janney,Adrian M. Di Bisceglie,Brent A. Neuschwander-Tetri,Bruce R. Bacon +4 more
TL;DR: There are no systems for grading necroinflammatory activity or for staging fibrosis as exist for various other forms of chronic liver disease and this study proposes a grading and staging system that reflects the unique histological features of nonalcoholic steatohepatitis.
Journal ArticleDOI
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Arun J. Sanyal,Naga Chalasani,Kris V. Kowdley,Arthur J. McCullough,Anna Mae Diehl,Nathan M. Bass,Brent A. Neuschwander-Tetri,Joel E. Lavine,James Tonascia,Aynur Unalp,Mark L. Van Natta,Jeanne M. Clark,Elizabeth M. Brunt,David E. Kleiner,Jay H. Hoofnagle,Patricia R. Robuck +15 more
TL;DR: Vitamin E was superior to placebo for the treatment of nonalcoholic steatohepatitis in adults without diabetes, and significant benefits of pioglitazone were observed for some of the secondary outcomes.
Journal ArticleDOI
Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference
Brent A. Neuschwander-Tetri,Brent A. Neuschwander-Tetri,Stephen H. Caldwell,Stephen H. Caldwell +3 more
TL;DR: The research agenda for the future includes establishing the role of insulin resistance and abnormal lipoprotein metabolism in NASH, determining the pathogenesis of cellular injury, defining predisposing genetic abnormalities, identifying better noninvasive predictors of disease, and defining effective therapy.
Journal ArticleDOI
Mechanisms of NAFLD development and therapeutic strategies
TL;DR: Understanding of pathogenic mechanisms and clinical features of NAFLD is driving progress in therapeutic strategies now in clinical trials and the emerging targets for drug development that involve either single agents or combination therapies intended to arrest or reverse disease progression are discussed.
Journal ArticleDOI
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri,Rohit Loomba,Arun J. Sanyal,Joel E. Lavine,Mark L. Van Natta,Manal F. Abdelmalek,Naga Chalasani,Srinivasan Dasarathy,Anna Mae Diehl,Bilal Hameed,Kris V. Kowdley,Arthur J. McCullough,Norah A. Terrault,Jeanne M. Clark,James Tonascia,Elizabeth M. Brunt,David E. Kleiner,Edward Doo +17 more
TL;DR: Obeticholic acid improved the histological features of non-alcoholic steatohepatitis, but its long-term benefits and safety need further clarification.